-
1 Comment
3SBio Inc is currently in a long term uptrend where the price is trading 11.6% above its 200 day moving average.
From a valuation standpoint, the stock is 97.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.9.
3SBio Inc's total revenue rose by 8.1% to $3B since the same quarter in the previous year.
Its net income has dropped by 79.6% to $133M since the same quarter in the previous year.
Finally, its free cash flow grew by 229.0% to $354M since the same quarter in the previous year.
Based on the above factors, 3SBio Inc gets an overall score of 4/5.
| Exchange | HK |
|---|---|
| CurrencyCode | HKD |
| Sector | Healthcare |
| Industry | Biotechnology |
| ISIN | KYG8875G1029 |
| Beta | 0.56 |
|---|---|
| Market Cap | 57B |
| PE Ratio | 5.77 |
| Target Price | 37.4275 |
| Dividend Yield | 1.0% |
3SBio Inc., an investment holding company, engages in the development, production, marketing, and sale of biopharmaceutical products in the People's Republic of China, the United States, and internationally. The company offers TPIAO bio-pharmaceutical drug for the treatment of chemotherapy-induced thrombocytopenia, immune thrombocytopenia, pediatric ITP, and chronic liver disease-related thrombocytopenia. It also provides EPIAO for indications, such as the treatment of anemia associated with chronic kidney disease, chemotherapy-induced anemia, and the reduction of allogeneic blood transfusion in surgery patients; and Yisaipu, a TNF-a inhibitor product for rheumatoid arthritis, ankylosing spondylitis, and psoriasis indications. In addition, the company offers Cipterbin, an anti-HER2 mAb for treatment of HER2-positive metastatic breast cancer in combination with chemotherapy; and Mandi, a minoxidil tincture for androgenetic alopecia and alopecia areata. Further, it develops 608, an anti-IL-17A mAb; SSS20 for patients with ITP and severe Aplastic Anemia; SSS06 for the treatment of adult dialysis patients undergoing erythropoietin therapy with a biweekly dosing interval; 613, for the treatment of acute gouty arthritis; 611, an anti-IL-4R a mAb; and 601A, an anti-VEGF mAb. Additionally, the company is involved in manufacture and sale of pharmaceutical drugs; business management; provision of technical services, investment advisory services, financial services, sports services, clinic services, technology services, and agricultural services; retail of pharmaceuticals; and enterprise management consulting. 3SBio Inc. was founded in 1993 and is headquartered in Shenyang, the People's Republic of China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 1530.HK using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2026
